We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go: Expired investment: £1,310,090
MGN Builders Merchants is a well-established, profitable, and a fast-growing builders merchants and skip hire based in London and Essex. It offers same or next day delivery on thousands of building products kept in stock at all times. Having served 50,000+ customers in 2018 (81k EBITDA), the company's client base includes small to medium-sized companies, private developers and DIY customers. In the last three years, the company has trebled its revenue from £2.5m in 2016 to £7m by January 2019, achieving an almost 100% sales increase YoY. MGN is raising funding to accelerate its rapid growth plans, expand its team, start selling online, and launch concrete delivery service to capture UK's £34bn construction supplied wholesale market.
days to go: Expired investment: £114,260
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.   
days to go: Expired investment: £152,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Go Modular design and build off-site modules for the construction industry. Using their innovative modular construction technology they aim to revolutionise the construction process making it more time efficient and less expensive to produce buildings. In 2018, Go Modular are looking to open their first factory in the UK which will enable them to offer the construction industry factory-produced building units that form the finished structure at the construction site.
days to go: Expired investment: £412,420
Polysolar specialises in manufacturing photovoltaic windows capable of generating electricity, which can be used in buildings to generate clean renewable energy whilst also meeting planning regulations. Its technology is already in-use by major organisations such as Network Rail and Sainsbury's.

Pitch Rated

69%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,311,180
A wind turbine's generator currently uses rare-earth magnets which cost £40 per kg, Greenspur have developed innovative generators which use ferrite magnets, an abundantly available material, that cost as little as £1 per kg. The company have made further advancements by removing the gearbox, which has resulted in lower maintenance costs and improved efficiency.
days to go: Expired investment: £368,640
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph